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ABSTRACT: Glycol chitosan nanogels have been widely used
in gene, drug, and contrast agent delivery in an eﬀort to
improve disease diagnosis and treatment. Herein, we evaluate
the internalization mechanisms and intracellular fate of
previously described glycol chitosan nanogels decorated with
folate to target the folate receptor. Uptake of the folate-
decorated nanogel was impaired by free folate, suggesting
competitive inhibition and shared internalization mechanisms
via the folate receptor. Nanogel uptake was shown to occur
mainly through ﬂotillin-1 and Cdc42-dependent endocytosis.
This was determined by inhibition of uptake reduction
observed upon siRNA depletion of these two proteins and the pathways that they regulate. The data also suggest the
involvement of the actin cytoskeleton in nanogel uptake via macropinocytosis. After 7 h of incubation with HeLa cells,
approximately half of the nanogel population was localized in endolysosomal compartments, whereas the remaining 50% of the
material was in undeﬁned regions of the cytoplasm. Glycol chitosan nanogels may thus have potential as drug delivery vectors for
targeting diﬀerent intracellular compartments.
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1. INTRODUCTION
Macromolecular micelles, commonly termed nanogels, have
been synthesized, characterized, and studied for numerous
biomedical applications including delivery of therapeutic
entities. Active nanogel targeting strategies have been conceived
to enhance their site-speciﬁc delivery by, for example,
decorating the surface with ligands of plasma membrane
receptors that are overexpressed on target cells.1
A major advantage in the use of nanoparticles as drug
delivery systems lies in their amenability to modiﬁcations that
allow them to cross biological barriers. The cell membrane is
naturally impermeable to complexes larger than 1 kDa;
however, nanoparticle uptake may occur through a variety of
active endocytic mechanisms, which depend on the phys-
icochemical features of the nanoparticle and the nature of the
target cells. For the successful development of nanocarriers, it is
crucial to understand the molecular mechanisms involved in
their interactions with the cell membrane in addition to their
entry via endocytic pathways and subsequent intracellular
fate.2−4
Generally, endocytosis can be divided into two broad
categories: phagocytosis (uptake of large particles) and
pinocytosis (uptake of ﬂuids, solutes, and ligands via plasma
membrane receptors). Phagocytosis is characteristic of
specialized professional phagocytes, whereas pinocytosis is
present in virtually all cells and has multiple forms depending
on the cell origin and function.5 Several diﬀerent classiﬁcations
for pinocytosis have been proposed, and a common approach is
to order these according to the key proteins involved: clathrin-
mediated endocytosis (CME), caveolae-mediated endocytosis
(CvME), clathrin- and caveolae-independent endocytosis, and
macropinocytosis. Clathrin- and caveolae-independent path-
ways can be further subclassiﬁed as Arf6-, ﬂotillin-1, Cdc42-,
and RhoA-dependent endocytosis.5−9
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The uptake mechanism of a drug delivery system is likely to
inﬂuence its intracellular fate and capacity to mediate a
biological response. The aim of the present study was to
identify the endocytic mechanisms responsible for the internal-
ization of glycol chitosan nanogels functionalized with folate in
HeLa (cervical adenocarcinoma) cells that overexpress folate
receptors.10 Conventionally, chemical endocytosis inhibitors
have been used to analyze cellular uptake of drug delivery
vectors including chitosan nanoparticles, but these inhibitors
are associated with problems related to toxicity and low
speciﬁcity.11−13 Selective inhibition of diﬀerent endocytic
pathways can also be attempted by siRNA targeting and
subsequent depletion of key proteins that orchestrate individual
pathways.14,15
In this work, single siRNA sequences were used to attenuate
pathways regulated by clathrin heavy chain (si-CHC), caveolin-
1 (si-Cav-1), p21-activated kinase 1 (si-Pak-1), Flotillin-1 (si-
Flot-1),14 and Cdc42 (si-Cdc42). The thus-treated cells were
then used to determine the mechanism of uptake and
intracellular fate of the nanogels to provide valuable
information regarding their capacity to deliver diﬀerent types
of cargos.
2. EXPERIMENTAL SECTION
2.1. Reagents. Glycol chitosan (GC, G7753), mercapto
hexadecanoic acid (MHDA), N-hydroxysulfosuccinimide
(NHS), 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide hy-
drochloride (EDC), O-methyl-O′-succinylpolyethyene glycol
2000 (PEG2000), O-(2-aminoethyl)-O′-(2-carboxyethyl)-
polyethylene glycol 3000 hydrochloride (PEG3000), folate, 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT), and sulforhodamine B (SRB) were purchased from
Sigma (St. Louis, MO, US). Folate-free RPMI 1640 medium,
Opti-MEM, oligofectamine, Alexa Fluor 647 Dextran (MW =
10.000, Alexa647−dextran), Alexa Fluor 647 transferrin
(Alexa647−transferrin), and Alexa Fluor 488 carboxylic acid
(succinimidyl ester; Alexa488) were bought from Invitrogen
(Carlsbad, CA, USA). Complete protease-inhibitor-cocktail
mini tablets were from Roche Diagnostics (Mannheim,
Germany). Single siRNA sequences of 21−23 residues were
acquired from Europhins MWG Operon (Ebesburg, Germany)
as previously described.14
2.2. Antibodies. Antibodies recognizing clathrin heavy
chain were from NeoMarker (California, US). Anti-Cav-1 was
from Cell Signaling Technology (Hertfordishire, UK). Anti-
Pak-1 was from Cell Signaling (Danvers, Massachusetts, US),
and antibody speciﬁc to Flot-1 was from BD Bioscience
(Oxford, UK). Anti-γ-tubulin was from Sigma (Dorset, UK).
Secondary goat antimouse- and goat antirabbit-HRP antibodies
were from Pierce (Loughborough, UK).
2.3. Cell Culture. HeLa cancer cells were cultured in
DMEM supplemented with 10% fetal bovine serum (FBS), 100
IU/mL penicillin, and 0.1 mg/mL streptomycin. The cells were
maintained as a subconﬂuent monolayer in a humidiﬁed
atmosphere containing 5% CO2 at 37 °C.
2.4. Self-Assembly of Nanogels. Details of GC nanogel
synthesis and characterization as folic acid functionalized
nanogels were described in a previous report.16 Brieﬂy, nanogel
synthesis was performed in two independent steps. Initially,
folate is conjugated to PEG3000 (FA-PEG3000). In the second
reaction, FA-PEG3000, PEG2000, and MHDA were grafted
onto the GC polymer. The nanogel dispersions used in the
diﬀerent experiments were obtained after dispersing the
lyophilized reaction product in distilled water under magnetic
stirring at 50 °C for 48 h and passing the product through a
pore size 0.45 μm cellulose acetate syringe ﬁlter.
2.5. Preparation of the Alexa488-Labeled Nanogel.
The nanogels were labeled with Alexa488 through an amide
linkage. Alexa488 was dissolved in DMSO. The molar ratio of
Alexa488 carboxylic groups to the nanogel free amine groups
was 0.11. The dye was added to nanogel dispersions at 1 mg/
mL in PBS and incubated in the dark at room temperature for
24 h. Thereafter, the reaction mixture was extensively dialyzed
(MW cutoﬀ = 10−12 kDa) against distilled water to remove
free Alexa488. To ensure the absence of free dye, the
conjugated Alexa488−nanogel was puriﬁed by centrifugation
at 3000 g through a 10 kDa MW cutoﬀ ﬁlter.
2.6. Cellular Uptake of Nanogels by Flow Cytometry.
HeLa cells were seeded onto 24-well plates at 2.0 × 105 cells
per well and left to adhere overnight. The cells were treated
with nanogels at 0.2 and 0.4 mg/mL for 0, 1, 3, 7, and 24 h.
After each time point, the mixture, culture medium, and
nanogel suspensions were removed, and the cells were washed
with PBS and collected using 150 μL of trypsin/EDTA (0.25%/
0.02%) in PBS, applied for 2 min at 37 °C; after addition of
FBS-supplemented medium, the cell suspension was centri-
fuged at 300 g for 10 min and rinsed with PBS. The cell-
associated ﬂuorescence was measured by ﬂow cytometry using
a Coulter Epics XL Flow Cytometer (Beckman Coulter Inc.,
Miami, FL, USA).
2.7. siRNA Transfection. The transfections were per-
formed as described by Soraj et al.14 Brieﬂy, cells were seeded
in antibiotic-free medium at a density of 1.6 × 105 cells per well
in a 35 mm glass-bottomed imaging dish (MatTek, Ashland,
USA) and in a 6-well plate. For 12-well plates, the density was
reduced to 6.7 × 104 cells per well. The cells were cultured
overnight to obtain the desired conﬂuency at the beginning of
the transfection (∼60%). The siRNA transfection procedure
was adjusted according to well diameter. Volumes used for a
12-well plate were: 0.5 μL of 50 μM stock siRNA diluted in
89.5 μL of Opti-MEM and 2.0 μL of oligofectamine in 8.0 μL
of Opti-MEM. The diluted solutions were then gently mixed
and stored at room temperature for 30 min. For each well, the
media was removed and replaced with 400 μL of Opti-MEM.
The siRNA−oligofectamine complex was added dropwise to
the wells and incubated at 37 °C and 5% CO2 for 4 h.
Thereafter, 250 μL of Opti-MEM containing 30% (v/v) of FBS
was added to the transfection mixture, and the cells were
incubated under tissue culture conditions for 48 h.
2.8. In Vitro Viability of the Transfected Cells.
2.8.1. MTT Assay. The eﬀect of siRNA transfection on cell
metabolic activity was evaluated using the quantitative
colorimetric MTT assay. The cells were seeded onto 24-well
cell culture plates at a density of 3.4 × 104 cells per well and
transfected with the diﬀerent siRNAs as described above. After
the transfection period (48 h), cell metabolic activity was
measured by adding MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide).17 The MTT solution (0.5 mg/
mL in PBS) was carefully removed from each well and the
resulting dark blue formazan crystals were solubilized in
dimethyl sulfoxide and quantiﬁed spectrophotometrically at
570 nm. A reference absorbance at 690 nm was measured for
the purposes of background subtraction.
2.8.2. SRB Assay. Cell proliferation of the siRNA-transfected
cells was assessed using the SRB assay, which provides an
estimate of total protein which in turn is related to cell
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number.18,19 After transfecting cells with siRNAs for 48 h, 24-
well plates were rinsed with PBS and left to dry at 37 °C under
5% CO2. Ice-cold 1% acetic acid/100% methanol solution was
then used to ﬁx the cells at −20 °C for 30 min. After discarding
the ﬁxative solution, the plates were left dry at 37 °C before
adding 250 μL of 0.5% SRB in 1% acetic acid to each well. At
90 min later, the cells were washed four times with 1% acetic
acid to remove the excess SRB and then left dry. A 1.0 mL
aliquot of 10 mM Tris solution was used to dissolve the SRB.
The supernatant was used for quantiﬁcation of SRB protein
staining that was quantiﬁed by a spectrophotometer at 540 nm.
2.9. Nanogel Internalization in Endocytosis-Compro-
mised Cells. 2.9.1. Fluorescence Microscopy. 2.9.1.1. Live-
Cell Imaging via Confocal Microscopy. siRNA-transfected
cells at 48 h post transfection (Section 2.7) in glass-bottomed
35 mm culture dishes were incubated with nanogels at 0.2 mg/
mL for 7 h. The cells were then rinsed extensively with PBS and
immediately imaged as live cells in phenol-red-free DMEM by
confocal microscopy at 37 °C on a Leica SP5 system as
previously described.14 Control and CHC-depleted cells were
also incubated for 16 min with the CME probe Alexa647−
transferrin (50 nM) to evaluate the eﬃciency of transfection.
2.9.1.2. Immnunolabeling. Cav-1 depletion was conﬁrmed
by immunolabeling and confocal microscopy. At the end of the
transfection, the cells on glass coverslips were rinsed with PBS
and ﬁxed with 3% PFA for 15 min at room temperature. Then,
the samples were treated with 50 mM of PBS/NH4 for 10 min
to quench reactive species resulting from ﬁxation. After PBS
washing (3×), the cells were permeabilised with PBS/0.2%
Triton X-100 and washed and immersed in blocking buﬀer (2%
(v/v) fetal calf serum and 2% (w/v) BSA in PBS) for 30 min.
Cells were then incubated with the primary antibody
recognizing Cav-1 and subsequently with Alexa546-labeled
secondary antibody. The cells were ﬁnally incubated in Hoechst
33342 for 10 min at room temperature to label the nucleus.
Finally, the coverslips were mounted on glass sides, and the
cells were visualized by confocal microscopy. Cells were imaged
through the z axis to generate z-projection images.
2.9.2. Flow Cytometry. Quantiﬁcation of cell-associated
ﬂuorescence in siRNA-transfected cells following incubation
with nanogel was performed by ﬂow cytometry. For this,
siRNA-transfected cells in a 12-well plate were incubated with
Alexa488−nanogel (0.2 mg/mL) for 7 h under tissue culture
conditions. The cells were then thoroughly washed with PBS
and trypsinised with trypsin/EDTA 0.25%/0.02% in PBS for 2
min at 37 °C; after addition of FBS-supplemented medium, the
cell suspension was centrifuged at 300 g for 10 min. The cell
suspension was washed with PBS. Cell-associated ﬂuorescence
of the cell suspension was measured using a Coulter Epics XL
Flow Cytometer (Beckman Coulter Inc., Miami, FL, USA).
2.9.3. SDS PAGE and Western Blotting. Following 48 h of
siRNA transfection, the cells from 6-well plates were washed in
ice-cold PBS and collected on ice by scraping in 100 μL of lysis
buﬀer (50 mM Tris-HCl, 150 mM NaCl, pH 8.0, 1% Triton X-
100) containing protease inhibitor cocktail. Lysates were then
centrifuged at 13 000 g (4 °C) for 10 min before adding three
parts supernatant to one part 4× Laemmli buﬀer. The samples
were heated at 95 °C for 5 min and centrifuged at 13 000 g (4
°C) for 1 min prior to loading onto 10% acrylamide gels for
separation by SDS-PAGE (18 μg of protein per well).
Following electrophoresis, the separated proteins were trans-
ferred to PVDF membranes that were rinsed with PBS and
blocked in 5% milk in PBS/Tween 20 (0.025%; PBST) for 1 h.
The membranes were then probed with antibodies recognizing
CHC, Cav-1, Pak-1, Flot-1, γ-tubulin, and β-actin diluted in 2%
milk in PBST. Following washing in PBST, species-speciﬁc
secondary antibodies conjugated to horseradish peroxidase
(HRP) and diluted in 2% milk in PBST were applied to the
membrane. Protein bands were detected by enhanced
chemiluminescence (ECL).
2.10. Nanogel Intracellular Localization. HeLa cells
were seeded at 3 × 105 cells in glass-bottomed dishes and left to
adhere overnight. Then, 0.2 mg/mL Alexa488−nanogel and
0.025 mg/mL Alexa647−dextran were coincubated with cells
for 7 h in folic-acid-free medium. In the case of the Alexa488−
nanogels, coincubation with Alexa647−transferrin (50 nM) was
performed by adding labeled transferrin complex 16 min before
the end of the nanogel incubation period (7 h). The cells were
extensively rinsed with PBS and immediately imaged as live
cells in phenol-red-free DMEM by confocal microscopy at 37
°C.
2.11. Statistical Analysis. Results are expressed as mean ±
SD of three independent experiments, each with n = 3.
Statistical signiﬁcances were determined by applying a one-way
ANOVA with a Dunnett’s multiple comparison test through
Prism software (GraphPad software version 5.00, USA).
Signiﬁcance of the results is indicated according to p values
(*, p < 0.05; **, p < 0.005; and ***, p < 0.0001).
Figure 1. Eﬀects of (A) nanogel concentration and (B) the presence of folate in the culture medium on the internalization of Alexa488−nanogel at
diﬀerent time points in HeLa cells. Mean ﬂuorescence intensity (MFI) was used as a proxy for ﬂuorescent nanogel uptake and was measured by ﬂow
cytometry at various time points up to 24 h (A) and 7 h (B).
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3. RESULTS AND DISCUSSION
We have previously shown that folate-functionalized glycol
chitosan nanogels have increased uptake over the unfunction-
alized nanogels.16 Herein, we investigate the uptake and
internalization properties of the folate functionalized nanogels.
3.1. Cellular Uptake of Nanogels as a Function of
Time, Concentration, and Presence of Folate. We
examined the eﬀects of folic acid functionalized nanogel
concentration and the presence of folate in the culture medium
on the internalization of Alexa488−nanogel at diﬀerent time
points. HeLa cells were incubated for diﬀerent time periods
with the ﬂuorescent nanogels at concentrations of 0.2 and 0.4
mg/mL in media either depleted of or containing folate. Cells
were collected, and the mean ﬂuorescence intensity (a proxy for
nanogel uptake) was measured by ﬂow cytometry.
Figure 1A shows that nanogel uptake increases with time
over a 24 h period in cells incubated with 0.4 mg/mL nanogel.
However, in cells incubated with 0.2 mg/mL nanogel, uptake
increases over the ﬁrst 7 h but then at some time during the 7−
24 h incubation period, the mean ﬂuorescence intensity
decreases. The data indicate not only reduced uptake at this
lower concentration but also a loss of the nanogel from the
cells. This suggests that during longer incubation periods (>7
h) at this concentration the ﬂuorescently labeled nanogel may
either be recycled out of the cell or degraded. Degradation
would seem more likely because recycling would potentially
lead to reuptake of the nanogel, so we would expect to see
stabilization in the level of internalized nanogel rather than loss.
Figure 1B demonstrates that internalization of the Alexa488−
nanogel is signiﬁcantly increased under folate-depleted culture
conditions compared with that of culture in normal media. The
presence of free folate in the culture medium has previously
been shown to lead to a decrease in uptake of folate-conjugated
nanoparticles by cells overexpressing folate receptors.7,20
Viewed in this context, we suggest that the folate receptors
may be involved in the internalization of the Alexa488−
nanogel, although other nonspeciﬁc mechanisms may also
contribute to the uptake. To eliminate the inhibitory and
potentially confounding eﬀects of folate in the media, folate was
eliminated from subsequent uptake experiments.
3.2. Inhibition of Endocytic Pathways through siRNA
Depletion of Endocytic Proteins. 3.2.1. Viability of siRNA-
Transfected Cells. The mechanism of nanogel internalization
was studied using siRNA transfection as a tool to silence
endocytic proteins and inhibit distinct endocytic pathways. It is
known that the level of cellular toxicity caused by transfection is
dependent on the reagent used and on the nature of the cells.
Cell proliferation and metabolic activity of HeLa cells
transfected using oligofectamine were studied to ensure that
viability was not compromised by the procedure. The metabolic
activity of HeLa cells was not signiﬁcantly aﬀected by
transfection (Figure 2A). Although statistically signiﬁcant
diﬀerences were detected in total protein levels, these are
relatively small and unlikely to be of biological signiﬁcance
(Figure 2B).
3.2.2. Cellular Uptake Mechanism(s) of the Nanogels by
Endocytosis-Compromised Cells. 3.2.2.1. Inhibition of Cla-
thrin-Mediated Endocytosis. Clathrin-mediated endocytosis
(CME) is the best-characterized mechanism of endocytosis and
requires the Adaptor-2 complex in association with clathrin
heavy and light chain.7,8 Cargos taken up by clathrin-coated
vesicles follow the classical endocytic pathway to early
endosomes where sorting occurs for delivery to other
organelles such as the lysosomes or back to the cell surface
through recycling endosomes.13 The uptake and recycling of
transferrin occurs through this endocytic pathway; hence, this
protein is commonly used as a marker to detect interference
with CME.14,21 CHC is the major coat protein associated with
this internalization pathway;7 thus in the present study, si-
CHC-transfected HeLa cells were incubated with Alexa647−
transferrin to evaluate the eﬃciency of CME inhibition.
Transferrin uptake in clathrin-depleted cells was visibly lower
compared with that of nontransfected and si-GFP transfected
cells (Figure 3A), reﬂecting successful and population-wide
transfection. CHC depletion was directly conﬁrmed through
CHC expression analyses in cell lysates (Figure 3B). To
ascertain if the nanogel utilizes this internalization pathway, si-
CHC-transfected HeLa cells and the respective controls were
incubated with nanogels and then analyzed via confocal
microscopy (Supporting Information Figure 1) and ﬂow
cytometry (Figure 3C), revealing no diﬀerences in nanogel
uptake between control cells and those deﬁcient in CME,
suggesting that this pathway is not involved in nanogel uptake.
3.2.2.2. Inhibition of Caveolae-Mediated Endocytosis.
Caveolae-mediated endocytosis (CvME) starts with the
formation of caveolae on the plasma membrane of cells, often
in lipid rafts. Caveolae are noted as being enriched in the
protein Cav-1 and have a diameter between 50 and 100 nm. A
dynamin-dependent scission of the caveolae from the
membrane then results in the formation of the endosome-like
caveosome.8 Initially, the caveosome interior was thought not
to acidify to any great extent with delivery of cargo to the Golgi
and/or endoplasmic reticulum, thus avoiding lysosomal
Figure 2. Eﬀect of the siRNA transfection on metabolic activity and
total protein mass of HeLa cells as assessed by the (A) MTT and (B)
sulforhodamine assays. *, p < 0.05, or ***, p < 0.001, represent the
statistical signiﬁcance of diﬀerences in viability between nontransfected
cells and the siRNA-depleted samples. Results are expressed as mean
± SD.
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degradation.8 However, Chiu et al.22 revealed that N-palmitoyl
chitosan nanoparticles enter cells via caveolae and were
transiently localized in caveosomes before traﬃcking to the
canonical endosomal pathway en route to lysosomes. Agents,
such as viruses, that are taken up by caveolae are also thought
to end up in endosomes that can be directed to lysosomes.
Evidence from electron microscopy studies suggests that
caveosomes represent a special type of caveolar endosome
that always associates with the plasma membrane.23 The theory
behind the existence of caveosomes mostly results from studies
that involve caveolin overexpression or caveolin mutants and as
such may or may not be a naturally occurring phenomenon.23
CvME inhibition was achieved through depletion of Cav-1
using transfection with si-Cav-1. Because Cav-1 is a critical
component of caveolae formation at the plasma membrane,8 its
depletion results in the impairment of CvME. The eﬃciency of
siRNA transfection was visualized by immunoﬂuorescence
microscopy of Cav-1 because a reliable endocytic marker
equivalent to transferrin for CME for assessing uptake via
caveolae has not yet been identiﬁed. As shown in Figure 4A, a
decrease in caveolin vesicle labeling was clearly observed in si-
Cav-1 transfected cells. Signiﬁcant Cav-1 depletion was also
conﬁrmed through Western blot analysis of cell lysates (Figure
4B).
There is data to suggest that folate internalization through
the folate receptor occurs via CvME.3 For example, folate-
targeted poly(ethylene glycol) (PEG)-coated nanoparticles
were thought to internalize via caveolae-assisted endocytosis,
and the nanoparticles were subsequently visualized in punctate
structures.24 Conversely, internalization and traﬃcking of folate
receptors was found not to be exclusively caveolae-dependent:
speciﬁcally, folate−protein conjugates, after binding to folate
receptors on the surface of cancer cells, were internalized
irrespective of size via uncoated pits or caveolae. However at
later times (6 h), some conjugates were found in lysosomes,
showing that the caveolae-mediated endocytic pathway
converged with a pathway utilized by clathrin-coated pits.25
In agreement with this, as shown by confocal microscopy in
Supporting Information Figure 2 and quantiﬁed by ﬂow
cytometry in Figure 4C, nanogel uptake was reduced, but not
signiﬁcantly (p ≥ 0.05), in Cav-1-depleted cells. However, it
should be noted that when a particular route is inhibited, others
may become activated as a compensatory mechanism.22 For
example, Cav-1 depletion has been shown to result in increased
levels of activated Cdc42 at the plasma membrane;5 this protein
is thought to regulate the actin cytoskeleton and folate
internalization through the glycosylphosphatidylinositol
(GPI)-anchored folate receptor.26
The hydrophobicity of the cargo may be a determining factor
for its internalization via CvME. The uptake of N-palmitoyl
chitosan nanoparticles was associated with lipid-raft-mediated
endocytic routes, and substitution of chitosan with a higher-
level palmitoyl groups (>10%) increased the fraction of nanogel
uptake via CvME.22
Also noteworthy is the impact of nanogel size distribution on
CvME and indeed on other pathways. The nanogels in this
study have mean diameters of around 200 nm, and size may
play a critical role in their mechanism of uptake. To our
Figure 3. CME inhibition in HeLa cells. (A) Confocal visualization of HeLa cells transfected with si-CHC or si-GFP (control) for 48 h prior to
incubation with Alexa647−transferrin for 16 min. For each condition (rows), the images correspond to (left to right, respectively) maximum
projection, middle z section through the cells, and diﬀerential interference contrast (DIC) images. Scale bars = 25 μm. (B) CHC expression after
transfecting HeLa cells with si-CHC for 48 h. (C) Eﬀect of the CME silencing on cellular uptake of nanogel, expressed as mean ﬂuorescence
intensity (MFI). Error bars represent SD.
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knowledge, no studies have unambiguously demonstrated that
caveolae can accommodate particles larger than 100 nm, and
this has previously been noted.27 However, CvME was thought
to play a major role in the cellular uptake of chitosan/DNA/
poly(γ-glutamic acid) complexes with an average size of
approximately 150 nm.28 It should be noted that most studies
suggesting that caveolae are involved in the uptake of drug
delivery vectors rely on the use of chemical endocytosis
inhibitors that often inﬂuence more than one pathway.12
3.2.2.3. Inhibition of Macropinocytosis. Macropinocytosis
is a poorly characterized pathway that internalizes extracellular
material in the ﬂuid phase. This process involves, especially
after growth factor activation, membrane ruﬄing and formation
of relatively large vesicles named macropinosomes. These are
heterogeneous in size, generally considered larger than 0.2 μm,
and have no clearly identiﬁed and unique coat structures.29,30 It
is known that p21-activated kinase (Pak-1) is associated with
growth-factor-induced macropinosomes14 and can be activated
by the small GTPases Cdc42 and Rac1.31 Whether the fate of
macropinosomes inside the cells involves fusion with lysosomes
or recycling to the plasma membrane or a mixture of both is
unclear and likely to be dependent on cell type.8
The addition of cationic molecules and particles to cells will
inevitably result in interaction with the negative surface,
mediated by surface sugars.2,3 This may or may not lead to
internalization via membrane turnover or activation of
macropinocytosis through ruﬄing. Membrane ruﬄing has
been extensively studied in the ﬁeld of cationic cell-penetrating
peptides.14,30 In the present study, we found that the cellular
uptake of the positively charged nanogel (+25 mV)16 was
signiﬁcantly aﬀected in Pak-1-depleted cells (Figure 5A,B).
Studies using chemical inhibitors in HeLa cells have
suggested that macropinocytosis plays a crucial role in the
Figure 4. CvME inhibition in HeLa cells. (A) Control and si-Cav-1- or GFP-treated cells were ﬁxed after 48 h, labeled with antibodies against Cav-1
and with Alexa546-conjugated secondary antibody, and then analyzed by confocal ﬂuorescence microscopy. Maximum projection (left) and a single z
section (right) is shown for each condition; nuclei are labeled with Hoechst 33342. Scale bars = 25 μm. (B) Cav-1 expression after transfecting HeLa
cells with si-Cav-1 for 48 h. (C) Eﬀect of the CvME inhibition on cellular uptake of nanogels expressed as mean ﬂuorescence intensity (MFI). Error
bars represent SD.
Figure 5. Pak-1 depletion of HeLa cells. (A) Inhibition of cellular
uptake of nanogel, expressed as mean ﬂuorescence intensity (MFI). **
represents statistical signiﬁcance of p < 0.01 for diﬀerences in nanogel
uptake between untransfected cells and si-Pak-1-transfected cells; error
bars represent SD. (B) Pak-1 expression after transfecting HeLa cells
for 48 h with control or si-Pak-1.
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internalization of hydrophobically modiﬁed glycol chitosan
nanoparticles (mean size = 350 nm and positive surface charge
= +22 mV).4 However, other uptake pathways were also
thought to be involved in uptake of these nanoparticles.
3.2.2.4. Inhibition of Clathrin- and Caveolin-Independent
Endocytosis: Cdc42- and Flotillin-Dependent Endocytosis.
Nanoparticles and polymers modiﬁed with folate have been
shown to bind to folate receptors that are often overexpressed
in tumor cells.6,32 These multiple GPI-anchored proteins (GPI-
Aps) are slowly internalized by cells and can be detected in a
population of early endosomal organelles referred to as GPI-
enriched early endosomal compartments, or GEECs. The
uptake process is not blocked by perturbations of CME.26,31
Cdc42-dependent endocytosis has been reported to be involved
in the uptake of GPI-Aps,23 and because of the actin mediated
eﬀects of Cdc42, it is also a well characterized regulator of
macropinocytosis.29 Raft-associated proteins ﬂotillin-1 and
ﬂotillin-2 are also thought to play a role in cellular uptake
and traﬃcking mechanisms of nanoparticles. Flotillin-1 has
been described as regulator of speciﬁc clathrin- and caveolae-
independent uptake mechanisms.15,23 Furthermore, ﬂotillins
appear to play a general function in late or lysosomal
degradation or storage processes.33
To investigate whether the nanogel internalization is aﬀected
by ﬂotillin-1 and/or Cdc42-dependent pathways, expression of
these proteins in HeLa cells was siRNA depleted prior to
performing uptake assays. The results shown in Figure 6A
demonstrate that cellular uptake is signiﬁcantly aﬀected in these
endocytosis compromised cells: nanogel uptake was inhibited
by approximately 70 and 65% in cells depleted of ﬂotillin-1
(Figure 6B) or Cdc42, respectively. We are currently unable to
label Cdc42 on membranes to investigate the extent of protein
depletion, but importantly, two diﬀerent sequences targeting
Cdc42 were shown to have almost identical eﬀects on nanogel
uptake.
The complete siRNA data presented in this study are
summarized in Figure 7, highlighting that the nanogel
internalization appears to be dependent on multiple endocytic
pathways. This has been previously reported for chitosan and
chitosan-derived nanoparticles using chemical inhibitors of
endocytosis.13,34 It remains to be determined whether the
nanogel is actually entering via a ﬂotillin- or Cdc42-mediated
pathway or even macropinocytosis, but it raises interesting
questions regarding the eﬀect of depletion of these proteins on
the overall organization of the plasma membrane. The eﬀects of
depletion of Cdc42 and Pak-1 also highlight the importance of
the actin cytoskeleton and most probably macropinocytosis in
the uptake of the nanogels. We suggest that nanogels enter the
cell through their activation of the cell membrane, promoting
their own uptake via actin reorganization and membrane
ruﬄing. Further experiments are required to test this hypothesis
more thoroughly.
Using siRNA to overcome the lack of speciﬁcity associated
with traditional chemical inhibitors, we are able to more
accurately target endocytic pathways utilized by the nanogel.
Diﬀerent pathways can be utilized to direct cargo to various
cellular destinations including the lysosomes, Golgi, or exocytic
structures for recycling. Overall, determining the uptake
mechanism utilized by a nanoparticle can signiﬁcantly aid in
the understanding of the nanoparticle’s ability to perform its
function and provide information for rational design of
improved delivery systems.
3.3. Nanogel Intracellular Localization. Once the key
mechanisms of nanogel internalization had been identiﬁed, we
aimed to investigate their intracellular fate by confocal laser
scanning microscopy. Determining the subcellular localization
of these vectors at diﬀerent time points can give important
information regarding their suitability for delivering therapeutic
cargo into cells and speciﬁc subcellular compartments. For this,
we made use of well-characterized endocytic probes whose
mechanism of uptake is understood, as is their eventual cellular
fate. The intracellular localization of the Alexa488−nanogel was
compared with transferrin and dextran, both labeled with
Alexa647. By using speciﬁc experimental conditions, these
probes can be used to identify early, recycling, and late
endosomes as well as terminal lysosomes.21,35
When internalized, iron-loaded holo-transferrin is traﬃcked
via clathrin-coated vesicles to early endosomes and then further
directed to recycling endosomes. Finally, it is returned to the
cell surface as apo-transferrin for another constitutive cycle of
iron loading.21 To determine if the nanogels enter the same
early/recycling endosomal compartment as transferrin, we
coincubated the two compounds for the ﬁnal 16 min of the 7 h
nanogel uptake period prior to performing live-cell confocal
microscopy. This short period allows the transferrin to traﬃc
to, and so label, early and recycling endosomes. The images and
Figure 6. (A) Flow cytometry analysis of the HeLa cells depleted of
ﬂot-1 or Cdc42 and incubated with Alexa488−nanogel for 7 h. Error
bars represent SD; *** indicates a statistical signiﬁcance of p < 0.001
for the diﬀerences in nanogel uptake between untransfected cells and
the siRNA-transfected cells. Error bars represent SD. (B) Flotillin-1
expression after transfecting HeLa cells for 48 h with siRNA targeting
Flot-1. CHC expression was measured as a loading control.
Figure 7. Mean ﬂuorescence intensity (MFI) of the nanogel
internalized by HeLa cells transfected with si-CHC, si-Cav-1, si-Pak-
1, si-Flot-1, and si-Cdc42, as measured by ﬂow cytometry. Untreated
cells and cells incubated with oligofectamine alone or transfected with
oligofectamine/si-GFP were tested as negative controls. At 48 h post-
transfection, the cells were incubated with nanogel, trypsinised, and
analyzed by ﬂow cytometry. **, p < 0.01, or ***, p < 0.001, represent
the statistical signiﬁcance of diﬀerences in nanogel between
untransfected cells and the remaining samples. Error bars represent
SD.
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colocalization data shown in Figure 8A−C demonstrate that
there is very little colocalization between transferrin and the
nanogel after they have entered the cell. This is expected on the
basis of data in Figure 3 and also the possibility that most of the
nanogels have traﬃcked to other endocytic compartments that
would be devoid of transferrin labeling, i.e., late endosomes and
lysosomes.
To test whether the nanogel was in fact being traﬃcked via
endolysosomal structures, nanogel/dextran coincubation ex-
periments were performed. These experiments revealed
considerable colocalization (∼50%) between nanogel and
dextran, as illustrated by colocalization of the two probes in
distinct intracellular yellow dots Figure 8D−F.
Cdc42 has also been shown to regulate ﬂuid-phase
endocytosis, and dextran enters cells via this mechanism.36
Thus, we infer from the data in Figure 8F that the nanogel
colocalized with the dextran represents the fraction of nanogel
that enters the cell in a Cdc42-dependent manner. This
conclusion is strengthened by our ﬁndings in Figure 6 that
Cdc42 is required for ∼70% of nanogel uptake. The absence of
complete colocalization may be attributed to the fraction that
enters the cell via lipid rafts and is thus regulated by the
expression of ﬂot-1. Previous studies by other researchers have
demonstrated a high extent of colocalization between acidic
organelles and hydrophobically modiﬁed glycol chitosan
nanoparticles in HeLa H2B-GFP cells labeled with LysoTracker
Red probe.4 Other research using human renal proximal tubular
KHC cells has shown that 50% of positively charged chitosan-
based nanoparticles could escape from lysosomes and reach the
cytosol after 6 h of incubation.37 Lower levels of colocalization
(∼20%) of hydrophobically modiﬁed glycol chitosan nano-
particles/lysosomal vesicles labeled with LysoTracker in HeLa
cells has also been noted.34
The data from this study suggest that a fraction of nanogel
may ultimately be delivered to lysosomes. This is not
unexpected because pathways such as CME, caveolae, and
macropinocytosis have been shown to deliver some ligands and
their receptors to lysosomes. However, because molecules such
as transferrin can enter cells via CME but are recycled rather
than degraded, it remains to be determined what, if any,
fraction of the nanogels recycles. The possibility exists that
recycling could be mediated by late endocytic structures via a
pathway that may be distinct from that used by transferrin.38
Although undesirable in many cases for therapeutic cargo
that would be inactivated in lysosomes, e.g., siRNA or DNA,
speciﬁc lysosome targeting may be beneﬁcial for drug delivery
strategies to replace deﬁcient lysosome enzymes to treat
conditions such as lysosomal storage diseases.39 Beyond this,
nanomedicines targeting the endolysosomal pathway also have
potential for improving drug delivery to address other major
disease burdens including Alzheimer’s disease and cancer.3,37
4. CONCLUSIONS
Inhibition of endocytic pathways via siRNA depletion of
speciﬁc endocytic proteins has provided new insights into the
way that nanogel enters cells with respect to the requirements
for speciﬁc proteins and the types of pathways that they
orchestrate.
Figure 8. Subcellular distribution of nanogel in HeLa cells after 7 h of incubation with (A−C) Alexa647−transferrin (16 min prior to analysis) or
(D−F) Alexa647−dextran (7 h coincubation). The images correspond to single-channel capture of nanogels (A and D, green in merge), transferrin
(B, red in merge), and dextran (E, red in merge) and respective merged images (C and F). Unﬁlled arrows show single nanogel structures, ﬁlled
arrows show single transferrin or dextran structures, and arrowheads show colocalization between nanogel and probe. Scale bars = 15 μm.
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The involvement of Cdc42 and Pak-1 strongly suggests that
actin reorganization is also required for uptake, but whether this
is constitutive or active macropinocytosis remains to be
determined. Colocalization studies with endocytic probes
showed that some nanogel is delivered to endolysosomal
compartments, but a signiﬁcant fraction was also in organelles
that await further characterization.
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